Starch Medical Launches New, Bioinert Surgical Hemostats

By admin On December 8, 2008

SAN JOSE, Calif., Dec. 2 /PRNewswire/ — Starch Medical Inc, a San Jose, CA-based medical device manufacturer, announces the CE approval of its PerClot(TM) Polysaccharide HemostaticSystem (PHS) and the StarFoam(TM) Absorbable Polysaccharide Hemostat. Introduction ofPerClot(TM) PHS will commence this month in the European Union and other select international markets. The StarFoam(TM) Absorbable Polysaccharide Hemostat will launch during the 2nd quarter, 2009.

PerClot(TM) PHS is an absorbable, surgical hemostat composed of Absorbable ModifiedPolymers (AMP(TM)). AMP(TM) technology incorporates sophisticated, plant-based polymer modification processes that yield biocompatible, polysaccharide particles. There is no thrombin,collagen, or other human or animal components in AMP(TM) particles. A family of customized,single-use application instruments will enhance the delivery of AMP(TM) to the wound site for the control of capillary, venous and arterial bleeding in both open and minimally invasive surgical procedures.

The StarFoam(TM) Absorbable Polysaccharide Hemostat, also developed with AMP(TM)technology, is produced in a hemostatic foam (wafer) configuration. Application ofStarFoam(TM) will feature a simple “press and release” technique.

David Lang, President of SMI, commented, “The clinical introduction of PerClot(TM) PHS and its proprietary, integrated AMP(TM) technology represents the next generation of polysaccharide hemostatic agents. The StarFoam(TM) product line will offer surgeons a choice of hemostatic formats for a range of surgical wounds. Compared to current polysaccharide based hemostats,PerClot(TM) PHS and StarFoam(TM) demonstrate superior hydrophilic action and enhanced adhesive strength. These performance features, coupled with custom delivery systems, have been favorably received in a diverse range of surgical applications in Europe, Asia and Latin America.”

SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. Starch Medical’s proprietary, patent pending technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide, multi-billion dollar biomaterial, hemostasis, and wound care marketplace.

For additional information, distribution inquiries, and licensing options

Contact: Jane Chen of Starch Medical Inc, +1-408-428-9818, jane@starchmedical.com

SOURCE Starch Medical Inc